Last reviewed · How we verify
Cabozantinib group
Cabozantinib group is a Small molecule drug developed by Hospices Civils de Lyon. It is currently FDA-approved. Also known as: CABOMETYX.
Cabozantinib is a small molecule used in the treatment of various conditions, including glioblastoma multiforme, neurofibromatosis 1, plexiform neurofibroma, rare tumors, and refractory tumors. It is administered orally as a tablet, and its exact mechanism of action is not specified in the provided information, but it is known to be a small molecule.
At a glance
| Generic name | Cabozantinib group |
|---|---|
| Also known as | CABOMETYX |
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas (PHASE1)
- Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies. (PHASE2)
- Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (PHASE2)
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma (PHASE2)
- Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity (PHASE2)
- Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) (PHASE4)
- Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma (PHASE4)
- TARGETed Therapy Drug MONITOring in DIGestive Oncology (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cabozantinib group CI brief — competitive landscape report
- Cabozantinib group updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about Cabozantinib group
What is Cabozantinib group?
Who makes Cabozantinib group?
Is Cabozantinib group also known as anything else?
What development phase is Cabozantinib group in?
Related
- Manufacturer: Hospices Civils de Lyon — full pipeline
- Also known as: CABOMETYX
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing